| Autor: |
I, Cokgor, G, Akabani, H S, Friedman, A H, Friedman, M R, Zalutsky, L M, Zehngebot, J M, Provenzale, C D, Guy, C J, Wikstrand, D D, Bigner |
| Rok vydání: |
2001 |
| Předmět: |
|
| Zdroj: |
Cancer. 91(9) |
| ISSN: |
0008-543X |
| Popis: |
Even with novel chemotherapeutic agents and external beam radiation therapy, the prognosis of neoplastic meningitis secondary to malignant melanoma is still dismal. The authors report a case study of a 46-year-old white female who presented with progressive hearing loss, severe headaches, nausea, vomiting, and a rapid decline in neurologic status. She was referred to Duke University Medical Center after conventional chemotherapy for malignant melanoma failed. She was enrolled in a Phase I trial of (131)I-labeled monoclonal antibody Mel-14 F(ab')(2) fragment administered intrathecally. Within a year after her treatment, she recovered, having a normal neurologic exam except for residual bilateral hearing loss. The authors discuss dosimetry, preclinical, and clinical studies conducted with Mel-14 F(ab')(2) and introduce a potentially promising therapy option in the treatment of neoplastic meningitis in patients with malignant melanoma. Currently, the patient remains neurologically normal except for a mild bilateral hearing loss more than 4 years after treatment and has no radiographic evidence of neoplastic meningitis. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text